Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 16 de 16
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
3.
Invest New Drugs ; 10(3): 159-63, 1992 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-1428725

RESUMO

From January 1983 through August 1988, 318 consecutive patients with refractory germ cell neoplasms were treated with ifosfamide-containing combination chemotherapy. The patients received ifosfamide at 1.2 gm/m2/day with cis-platin 20 mg/m2/day for 5 days and etoposide 75 mg/m2/day for 5 days or vinblastine 0.11 mg/kg on days 1 and 2 for each cycle. Of 277 evaluable patients, NAC was used as an uroprotector in the initial 86 patients while the latter 191 consecutive patients received mesna to reduce urothelial toxicity. Dosages of NAC was 2.0 gm po q 6 hr and for mesna 120 mg/m2 IV push prior to ifosfamide and then 1200 mg/m2/day as continuous infusion of 5 consecutive days. All patients received 3.0 liters of normal saline per day. The number of courses of chemotherapy given in the two groups were similar. Twenty-four of the 86 patients (27.9%) receiving NAC developed hematuria (13 patients - grade 1, 4 patients - grade 2, and 7 patients - grade 3 toxicity). While 8 out of 191 (4.2%) mesna patients developed hematuria (6 - grade 1 and 2 - grade 3) (p < 0.0001). The incidence of severity of renal toxicity was similar in the two groups. Ifosfamide dosage was reduced solely for urothelial toxicity in 11 patients receiving NAC compared with none of the patients receiving mesna (p < 0.0001). Chemotherapy response was similar in the two groups. In conclusion, mesna provides better urothelial protection from ifosfamide-induced toxicity than NAC and allows better maintenance of the drug dosage.


Assuntos
Acetilcisteína/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Disgerminoma/tratamento farmacológico , Hematúria/prevenção & controle , Ifosfamida/efeitos adversos , Mesna/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Cisplatino/administração & dosagem , Etoposídeo/administração & dosagem , Hematúria/induzido quimicamente , Humanos , Masculino , Índice de Gravidade de Doença , Vimblastina/administração & dosagem
4.
J Pers Assess ; 59(2): 276-89, 1992 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-16370846

RESUMO

This article is an extension of the Ben-Porath and Butcher (1989a) study, investigating the claim that the scores and configural patterns of the Minnesota Multiphasic Personality Inventory-2 (MMPI-2) are consistent with those of the Minnesota Multiphasic Personality Inventory (MMPI). College students (200 men and 200 women) were randomly assigned to either the original to original condition (O-O), in which they took the MMPI twice, or the original to revised condition (O-R), in which they took the MMPI and the MMPI-2. Correlations and configural patterns of the O-O condition were compared to those of the O-R condition. Results suggest some score changes between the MMPI and MMPI-2, particularly on Scales L, 5, and 8 for men and Scales L and 5 for women.

7.
Lancet ; 1(8592): 998-9, 1988 Apr 30.
Artigo em Inglês | MEDLINE | ID: mdl-2896862
15.
Pa Med ; 72(3): 66-8, 1969 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-5783699
16.
Med Times ; 96(10): 988-96, 1968 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-5680463
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...